The diabetes testing supplies industry last week was questioning the “inherent reasonableness” rule that CMS may employ as an alternative to competitive bidding in lowering Medicare payment for diabetic testing supplies sold at retail.
If the agency moves forward with a proposal to use the relatively obscure rule to adjust reimbursement for non-mail order diabetic testing supplies – blood glucose strips, lancets or related...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?